Comparative Pharmacology
Head-to-head clinical analysis: ESGIC PLUS versus PHRENILIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESGIC PLUS versus PHRENILIN.
ESGIC-PLUS vs PHRENILIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esgic-Plus is a combination of acetaminophen (analgesic/antipyretic via COX inhibition and central action), butalbital (barbiturate that enhances GABA-A receptor activity), and caffeine (adenosine receptor antagonist and CNS stimulant). The mechanism for treating tension headache is attributed to the synergistic effects of these components.
PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.
1-2 capsules (acetaminophen 500 mg, butalbital 50 mg, caffeine 40 mg per capsule) orally every 4 hours as needed, not exceeding 6 capsules per day.
For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
None Documented
None Documented
Butalbital: 35-70 hours in adults; prolonged in hepatic/renal impairment. Acetaminophen: 2-3 hours in adults; extended in overdose (potential hepatotoxicity). Caffeine: 3-6 hours in adults; increased in pregnancy or liver disease.
Butalbital: terminal half-life ~35 hours (range 20-50 h); acetaminophen: ~2-3 hours (prolonged in hepatic impairment); caffeine: ~3-6 hours.
Butalbital: 60-90% renal as unchanged drug and metabolites, 10-40% fecal via biliary elimination. Acetaminophen: ~85% renal as glucuronide (45-55%), sulfate (25-35%), and cysteine conjugates (4-15%); 2-4% unchanged. Caffeine: ~85-90% renal as metabolites (1-methylxanthine, 1-methyluric acid, 1,7-dimethylxanthine); 1-3% unchanged.
PHRENILIN (butalbital/acetaminophen/caffeine): Renal excretion of metabolites; butalbital ~60-70% unchanged in urine, acetaminophen ~2-4% unchanged with majority as glucuronide and sulfate conjugates, caffeine metabolites primarily renal.
Category C
Category C
Barbiturate/Narcotic Combination
Barbiturate/Analgesic Combination